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X-LAG: How did they grow so tall?
X-LAG ou comment sont-ils devenus si grands ?
Albert Beckers a,∗, Liliya Rostomyan a, Iulia Potorac a, Pablo Beckers b, Adrian F. Daly a
a Department of Endocrinology, Centre Hospitalier Universitaire de Liège, University of Liège, 4000 Liège, Belgium
b Department of Clinical Biochemistry, Centre Hospitalier Universitaire de Liège, University of Liège, 4000 Liège, Belgium
bstract
X-linked acrogigantism (XLAG) is a new, pediatric-onset genetic syndrome, due to Xq26.3 microduplications encompassing the GPR101  gene.
LAG has a remarkably distinct phenotype with disease onset occurring before the age of 5 in all cases described to date, which is significantly
ounger than in other forms of pituitary gigantism. These patients have mixed GH and prolactin positive adenomas and/or mixed-cell hyperplasia
nd highly elevated levels of GH/IGF-1 and prolactin. Given their particularly young age of onset, the significant GH hypersecretion can lead to
 phenotype of severe gigantism with very advanced age-specific height Z-scores. If not adequately treated in childhood, this condition results in
xtreme final adult height. XLAG has a clinical course that is highly similar to some of the tallest people with gigantism in history.
 2017 Elsevier Masson SAS. All rights reserved.
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ésumé
« X-linked acrogigantism » (XLAG) est un syndrome pédiatrique récemment décrit, lié à des microduplications du chromosome Xq26.3,
nglobant le gène GPR101, responsable de l’affection. Les patients XLAG présentent un phénotype remarquablement distinct des autres cas de
igantisme hypophysaire. Dans tous les cas décrits, la maladie s’exprime avant 5 ans soit beaucoup plus tôt que dans les autres formes. Les patients
nt habituellement un gros adénome ou une hyperplasie mixte pour la GH et la prolactine et des taux très élevés de GH/IGF1 et prolactine. En raison
e son début très précoce, l’hypersécrétion importante de GH peut conduire à un gigantisme extrêmement sévère avec un Z-score très important
our l’âge. Si cette condition n’est pas traitée pendant l’enfance, elle peut conduire à une taille finale extrême. XLAG montre une évolution clinique
imilaire à celle observée chez les géants les plus grands de l’histoire. 2017 Elsevier Masson SAS. Tous droits re´serve´s.





Acromegaly and gigantism result from chronic excessivePlease cite this article in press as: Beckers A, et al. X-LAG: H
http://dx.doi.org/10.1016/j.ando.2017.04.013
roduction and secretion of growth hormone (GH), usually by
 pituitary adenoma, and are considered very rare conditions.
H-secreting pituitary tumors are predominantly sporadic
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003-4266/© 2017 Elsevier Masson SAS. All rights reserved.esions that occur in adults, although rare pediatric or familial
orms can occur and these can have aggressive characteristics.
he molecular genetics of these aggressive forms of soma-
otropinomas is of interest for research and clinical practice.
nown genetic syndromes associated with the occurrence
f somatotropinomas include multiple endocrine neoplasiaow did they grow so tall? Ann Endocrinol (Paris) (2017),
MEN) type 1 and MEN 4, Carney complex, McCune–Albright
yndrome (MAS), and pheochromocytoma/paraganglioma and
ituitary adenoma syndrome (3PAs). The most frequent familial
orm of pituitary adenoma is familial isolated pituitary adenoma
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big. 1. Growth pattern (panel A) and physical characteristics (panel B) of a p
ithout a history of gigantism and had already established abnormal linear gro
ecreting pituitary tumor [4].
FIPA) syndrome [1]. Approximatively 15–20% of general
IPA kindreds and about 50% of homogeneous FIPA families
ith acromegaly-gigantism are caused by mutations/deletions
n the aryl  hydrocarbon  receptor  interacting  protein  (AIP) gene
2,3].
In Trevellin et al., we recently described an international
ohort of patients with a new genetic form of pituitary gigan-
ism beginning in early childhood due to a microduplication on
q26.3, that we termed X-linked acrogigantism (XLAG) [4]. In
 large pituitary gigantism-specific cohort study of 208 patients,
e found that AIP  mutations and XLAG accounted for 29%
nd 10%, respectively, of genetically tested patients, making
hem the two most common causes of pituitary gigantism.
he previously known genetic causes of somatotropinomas are
esponsible for a much lower percentage of pituitary gigan-
ism cases: MAS (5%), MEN1 (1%), and Carney complex (1%)
5]. To date, 32 patients with XLAG duplications have been
ublished in the scientific literature [4,6–11]. Notably, XLAG
xplains the majority of prepubertal cases (80%) and almost all
f the tallest cases in our 208-patient cohort; these XLAG cases
anifested with either exceedingly excessive growth rate or a
ery increased final adult height (height Z-score > +4.5 SD).
.  Clinical  proﬁle
XLAG is a pediatric syndrome of pituitary gigantism with
 very young age of disease onset. Usually increased lengthPlease cite this article in press as: Beckers A, et al. X-LAG: H
http://dx.doi.org/10.1016/j.ando.2017.04.013
nd weight are seen before the age of 1 year and most patients
re diagnosed by the age of three with already substantially
dvanced overgrowth [4,9,12]. This young age at first mani-




pwith Xq26.3 duplication. She was born to normally-sized parents in a family
nd acral overgrowth by the age of 12 months, caused by a GH- and prolactin-
rom other forms of gigantism and acromegaly. Genetic forms of
omatotropinomas, particularly AIP-related, are more frequent
n younger patients than in the general sporadic acromegaly
opulation [5]. AIP-related cases, however, usually occur in
dolescents and young adults, whereas children with XLAG,
ho are usually born with normal anthropometric parameters
fter uncomplicated pregnancies, begin their abnormal growth
n infancy (Fig. 1A) [4]. This means that patients with XLAG
an have had a long duration of overgrowth by the time they
each puberty, which translates into increased height Z-scores
s compared with other forms of pituitary gigantism [5].
Besides the early excessive acceleration of linear growth and
ody size, these young patients frequently present some clinical
igns and symptoms of GH/IGF-1 excess that are more typical
f adult acromegaly (Fig. 1B). They may develop soft tissue
welling and coarse facial features and an increased interdental
pace, as well as marked enlargement of hands and feet [12].
n some cases, increased appetite (25%) and signs of insulin
esistance (such as acanthosis  nigricans) are also noticed at
iagnosis [12]. XLAG has a female predominance (71%); this
eature differentiates it from AIP-mutation related gigantism
ases and gigantism patients without a known genetic cause in
hich cases most of the affected subjects are males (95% and
8%, respectively) [5].
In both male and female XLAG cases, the extraordinary
rowth velocity and prolonged linear growth is underpinned
y the aggressive behavior of the pituitary lesion [4,12]. Chil-ow did they grow so tall? Ann Endocrinol (Paris) (2017),
ren with XLAG develop relatively large pituitary adenomas
or their young age (Fig. 2), which can be accompanied by
ituitary hyperplasia. In some cases, diffuse hyperplasia can be
resent alone and it is unknown whether the mixed GH-prolactin
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Fig. 2. Coronal and sagittal MRI images of patients with XLAG. Panels A and B. A large pituitary mass with important suprasellar extension in a female patient
was revealed by gadolinium-enhanced MR imaging at diagnosis (2 years 11 months). Panels C and D. Gadolinium-enhanced MR images of a female patient, who





























aostoperative images from the same patient with resected adenoma. However, th
or hormonal and growth control. Panels G and H show MR images of a fem
xtrasellar expansion [12].
ecreting macroadenomas that are seen in most XLAG patients
egin as hyperplasia before transforming into adenoma. Pathol-
gy studies have demonstrated foci of transformation fromPlease cite this article in press as: Beckers A, et al. X-LAG: H
http://dx.doi.org/10.1016/j.ando.2017.04.013
yperplasia to adenoma, which further supports the concept
hat the adenomas in XLAG develop against a background of





istorical cases of extreme gigantism in which growth began in early childhood [12]
ame Country Sex Year of birth 
artin Van Buren Batesa USA M 1837 
nna Haining Swana Canada F 1846 
lla Kate Ewing USA F 1872 
edor Andreevich Machnow Russia M 1878 
douard Beaupréb Canada M 1881 
oh(a)n Aasenb USA M 1890 
lbert Johan Kramerb The Netherlands M 1897 
obert Pershing Wadlowb USA M 1918 
ecil Boling USA M 1920 
igardus Rijnhoutb The Netherlands M 1922 
olores Ann Pullardb USA F 1946 
andra Elaine (Sandy) Allenb USA F 1955 
eng Jinlian China F 1965 
ao Defenb China F 1972 
a Swan and Bates were married and had two pregnancies; one female child was sti
nd 76 cm in length when born.
b Cases for which pituitary disease was reliably diagnosed/reported.inistration of SSA and pegvisomant were required after surgery in this patient
atient at diagnosis (aged 3 years) presenting with a large pituitary mass with
We recently showed that modestly elevated circulating GH
eleasing hormone (GHRH) levels can occur in XLAG [13].
HRH levels in XLAG are not as high as those usuallyow did they grow so tall? Ann Endocrinol (Paris) (2017),
ncountered in ectopic GHRH secretion from neuroendocrine
arcinomas. Moreover, intense GHRH-receptor (GHRH-R)











Normal Y 6 222
8.1 Y < 4 227
3.4 Y 7 225
NA Y 5 239
4.1 Y 3 251
NA No < 8 218
8.5 Y < 7 238
4.1 Y < 3 272
Normal Y < 7 235
Normal Y > 3 238
Normal Y 4 227
2.95 Y 3 232
Normal Y < 1 249
2.8 Y < 3 234
llborn (weighed 8.1 kg) and later a son who died in early infancy was 10.8 kg
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wig. 3. Photographs of some of the tallest historical patients presented in the orde
ituitary gigantism, which is an important feature of the XLAG syndrome. Two
4,12,13]; which suggests that the cell population involved in
yperplasia and adenomatous transformation may be sensitive
o GHRH. Furthermore, in  vitro  cell culture studies of an XLAG
ituitary lesion revealed that a GHRH-R antagonist inhibited
oth GH and prolactin and antagonised the effect of GHRH
timulation. These data support hypothalamic involvement via
HRH and GHRH-R dysregulation in the pathogenesis of
LAG. The GHRH-related GH hypersecretion in XLAG could
otentially be targeted by therapeutic blockade of the GHRH-R
13].
In terms of treatment, XLAG patients have particularly dif-
cult to treat pituitary lesions, not only due to their young
ge and relatively large tumor size. They often require multi-
odal treatment, including pituitary surgery, medical treatment
nd radiotherapy. Almost all XLAG cases have partial or com-
lete resistance to octreotide/lanreotide, despite a relatively high
xpression of somatostatin receptor type 2 [12]. Prolactin hyper-
ecretion demonstrates variable responsiveness to dopamine
gonist therapy. In order to control GH hypersecretion, some
atients have required aggressive surgical resection (includ-
ng anterior hypophysectomy when extensive hyperplasia has
een present), in combination with radiotherapy. The conse-
uences of these multiple lines of treatment is the frequent
ccurrence of partial or complete hypopituitarism, requiring
ifelong replacement therapy starting from a very young age.
djuvant use of the GH receptor antagonist, pegivsomant,
as proven successful in controlling GH secretion in some
LAG patients [12]. Prompt and effective hormonal control is
 key requisite in halting linear growth before patients reach a
arkedly increased adult height [5]. In the absence of effective
easures to control tumor growth, marked tumor progression
an continue in XLAG, with exceptionally severe phenotypes
f pituitary gigantism being established before puberty [7].
 number of patients with extremely gigantism described inPlease cite this article in press as: Beckers A, et al. X-LAG: H
http://dx.doi.org/10.1016/j.ando.2017.04.013
istorical and medical records had clinical presentations that
orresponded to the growth pattern of XLAG patients [4,12].
n particular, the tallest man, Robert Wadlow, and the tallest




neir height. They appeared from medical records as having early childhood-onset
 silhouettes illustrate the average human height (175 cm).
haracteristics of XLAG patients with rapid overgrowth in early
hildhood (Fig. 3).
.  Genetics
XLAG has a specific genetic etiology. Unlike the other pitu-
tary adenoma-associated genetic syndromes usually caused by
nactivating mutations or deletions in tumor suppressor genes or
ctivating mutations in an oncogene, XLAG is due to a dupli-
ation on chromosome Xq26.3. Array comparative genomic
ybridization (aCGH) is usually used for detecting such copy
umber variation (CNV) abnormalities. All 18 XLAG patients in
ur initial cohort were found to have microduplications with two
mallest regions of overlap, encompassing four genes (CD40LG,
RHGEF6, RBMX  and GPR101) [4]. Among the initial four can-
idate genes, GPR101, an orphan G-protein coupled receptor
ene, was shown to be the only one significantly overexpressed
n the pituitary tissue of patients with Xq26.3 microduplications.
he causative pathogenic role of the GPR101  gene in XLAG
as thereafter supported by a XLAG patient with duplication of
PR101 alone [8].
GPR101 is an orphan Gs protein-coupled receptor, whose
ndogenous ligand and exact functions are unknown. GPR101
s normally expressed at particularly high levels in the mouse
ypothalamus and in the pituitary of the rhesus macaque and the
at. In humans, GPR101 mRNA is predominant in the nucleus
ccumbens and its expression is low in adult pituitary gland.
owever, GPR101 might have a role during pituitary ontoge-
esis. GPR101 expression was found in the pituitary gland of
uman embryos starting from 19 weeks of gestational age with
he highest levels of GPR101 staining (65%) at 38 weeks [4,14].
PR101 duplication might support mixed GH and prolactin pos-
tive cellular hyperplasia in XLAG starting from the fetal period
ith further adenoma formation in the early period after birth.ow did they grow so tall? Ann Endocrinol (Paris) (2017),
owever, the role of GPR101  in pituitary development, tumori-
enesis and stimulation of GH/prolactin hypersecretion remains
nclear. So far, inactivating mutations of the GPR101  gene do
ot seem to be commonly involved in GH deficiency [15].
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(ig. 4. Genomic gains on HD-aCGH in three sporadic males. The theoretical Lo
s the red line. The LR values of the XLAG duplications identified in each subje
Most XLAG cases are sporadic and duplications in all spo-
adic cases appear to be non-recurrent with unique boundaries.
hese are generally due to a DNA replication error because of
icrohomologies between proximate fragments at Xq26.3 [4].
n familial cases, a transmission of the same XLAG microdu-
lication from affected mother to affected son with 100%
enetrance has been reported in three homogeneous FIPA kin-
reds with early onset acrogigantism [4,11]. Along with AIP
utation/deletion, XLAG is the second known genetic cause of
IPA in AIP-negative kindreds with familial acrogigantism.
While the GPR101  duplication has been found in all the
LAG cases reported so far, in sporadic males the aCGH result
emonstrates the presence of somatic mosaicism that leads to a
ariable proportion of affected cells (Fig. 4) [9]. Relatively low
evels of GPR101  duplicated cells (as low as 16–17%) have been
onfirmed using digital droplet PCR (ddPCR), which allows thePlease cite this article in press as: Beckers A, et al. X-LAG: H
http://dx.doi.org/10.1016/j.ando.2017.04.013
etection of quite small rates of mutations or CNV–deletions
r duplications (Fig. 5). The clinical presentation of XLAG
n all mosaic cases is similar to that of patients with constitu-





ig. 5. Mosaicism-level quantification by HD-aCGH (panel A) and ddPCR (panel B
1 case), familial males (3 cases) and sporadic males (3 cases) with XLAG syndromeo (LR) value of heterozygous duplication on X chromosome in males is marked
ack lines) were found to be lower than the theoretical LR in all three cases [9].
everity. Thus, sporadic males could exhibit dramatic forms
f pituitary gigantism even when only a low proportion of
ells carry the GPR101  duplication. We screened a large group
f patients with acromegaly and gigantism using quantitative
dPCR for GPR101  duplications. This method allows the iden-
ification of new XLAG cases by means of increased GPR101
opy number, which can later be confirmed on aCGH [9].
Recently, we further applied this screening ddPCR method
o ancient DNA retrieved from skeletal remains of a historical
ase of extreme acrogigantism (giant Constantin; 259 cm). The
ndividual died of septicemia following surgery for gangrene as
 young adult in 1902, and his autopsy demonstrated a massively
nlarged pituitary gland and pituitary fossa [10]. According to
ublished sources and original medical documentation avail-
ble to us, the abnormal growth started early and extremely tall
tature (1.94 m) was already present at the age of 14. Paleonto-ow did they grow so tall? Ann Endocrinol (Paris) (2017),
ogical DNA extraction techniques permitted the extraction of
NA from bone powder and subsequent ddPCR revealed ele-
ated copy number of GPR101  indicating a probable diagnosis
f XLAG (Fig. 6).
) in sporadic females (average mosaicism level in 11 cases), familial female
 [9].
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Fig. 6. A historical case of dramatic gigantism, the giant Constantin, who measured 259 cm. He was photographed for a poster while visiting Belgium in Novem-
b panel



















[er 1901, at which time he had extremely tall stature and acromegalic features (
nd enlargement of the malar bones. An enlarged sella turcica is marked by the
btained by drilling a small amount of bone powder (filled arrow) [10].
.  Conclusion
XLAG syndrome is characterized by a very specific pheno-
ype of infant-onset gigantism with markedly increased height
nd weight z-scores. It is caused by mixed GH and prolactin
ecreting pituitary adenomas and/or hyperplasia that can pro-
uce exceptionally high levels of GH and prolactin. This new
enetic from of pituitary gigantism is due to the duplication
f the GPR101  gene and can present either sporadically (as
onstitutional or mosaic duplication) or in a FIPA setting. To
ate, 32 XLAG patients have been reported, most of whom are
emales. XLAG is a clinical entity that, while rare, leads to an
xceptionally severe pituitary gigantism phenotype that requires
arly intervention to control overgrowth.
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